Biospot Bioaerosol Sampler Tender in USA - 30173876

Procurement Summary

Country: USA

Summary: Biospot Bioaerosol Sampler

Deadline: 07 Feb 2019

Posting Date: 29 Jan 2019

Other Information

Notice Type: Tender

TOT Ref.No.: 30173876

Document Ref. No.: FDA-1207922

Competition: ICB

Financier: Self Financed

Purchaser Ownership: -

Tender Value: Refer Document

CPV Classification

38300000 - Measuring instruments

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

This is a combined synopsis/solicitation for commercial items prepared in accordance with the federal acquisition regulation (far) format in subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. It is the government's intent to issue a firm fixed priced purchase order in accordance with far part 13.
The solicitation number is fda-1207922. This solicitation is issued as a request for quote (rfq).
The solicitation document and incorporated provisions and clauses in effect through the federal acquisition circular 2019-01 dated january 22, 2019.
The appropriate naics code for the acquisition is 334519 -- other measuring and controlling device manufacturing; small business size standards - 500 employees. This requirement is being competed as a total small business set-aside.
Background/statement of need:
the u.s. Food and drug administration (fda), center for biologics evaluation and research (cber) requires a biospot bioaerosol sampler. The instrument will be used for detection of live b. Pertussis in the air of rooms housing b. Pertussis-infected animals. The capability will allow the ability to evaluate existing and experimental pertussis vaccines to reduce or prevent shedding of bacteria into the environment.
Minimum technical requirements:
1. Shall include prototype version with higher volume sampling capacity.
2. Shall include high efficiency collection of viruses, bacteria, spores, toxins and exhaled proteins.
3. Shall provide gentle collection into liquid through condensationally-enhanced inertial deposition,
4. Shall include new 3 stage condensation growth technology with minimal heating of the airflow minimizes loss of volatile constituents, reduces thermal decomposition, and maintains microorganism viability.
5. Shall include uninterrupted, time resolved sampling...

Documents

 Tender Notice